Introduction. The objective of this study was to estimate the effects of different doses of oral hormone therapy (HT) on thrombin generation and fibrinolytic activity in postmenopausal women after 12 months of treatment. Material and methods. Thrombin generation, fibrinolysis activators and inhibitors were determined before and after 12 months of treatment. Participants (180) were assigned (1:1:1) as follows: (1) standard HT group, 17b-estradiol (1 mg/day) with dydrogesterone (5 mg/day); (2) ultra-low dose HT group, 17b-estradiol (0.5 mg/day) with dydrogesterone (2.5 mg/day); (3) control group, no treatment. Results. The standard HT led to a higher concentration of prothrombin 1 + 2 fragment (by 5.8%) with lower antithrombin activity (by 6.1%). Compared with baseline, we observed a reduction in mean antithrombin activity in the standard HT group and increases in mean levels of prothrombin 1 + 2 fragment in two HT groups. We found decreases after treatment in both standard and ultra-low dose HT groups in plasminogen activator inhibitor-1 (PAI-1) activity (À32.4% and À19.6%, respectively) and PAI-1 antigen (À9.9% and À7.8%, respectively). Intergroup analysis revealed reduction in both mean PAI-1 activities and PAI-1 antigen levels in the two treatment groups when compared with the control. Conclusion. Contrary to the standard estrogen plus dydrogesterone treatment, ultra-low dose HT revealed positive effects on hemostasis by intensifying fibrinolysis through a decrease in both PAI-1 activity and antigen levels, and with no impact on thrombin generation.
Introduction
Estrogen changes, which occur during perimenopausal period, may lead to hot flushes, night sweats, loss of libido and mood changes. Hormone therapy (HT) continues to be the most efficient treatment for climacteric symptoms (1, 2) . However, venous thromboembolism (VTE) is a major side effect associated with HT (3). VTE occurs with an incidence of about 1 per 1000 postmenopausal women aged 50 years and it increases with age (4). It has been consistently reported that HT users have two-to threefold higher risk of VTE, especially during the first year of the treatment (3) . The mechanism whereby HT provokes an increased risk of VTE is unclear.
The fibrin clot formation is the final step in blood coagulation. Effective fibrinolysis is essential in maintaining vessel patency. However, highly branched fibrin clots associated with impaired fibrinolysis have been shown in patients with VTE (5) .
Several studies consistently showed that HT alters blood coagulation by reducing levels of natural anticoagulants such as activated protein C (APC) and antithrombin (AT) and by increasing thrombin generation (6) . On the other hand, it has been reported that combined HT enhances fibrinolytic potential, represented by a decrease in fibrinogen concentration and a lower plasminogen activator inhibitor-1 (PAI-1) activity (7) .
It has been suggested that differences in the formulation, dose and duration of HT may affect the risk of VTE (1, 4) . So far, several studies confirmed that oral, but not transdermal, HT administration increases plasma levels of procoagulant factors VII, X, XII and prothrombin fragment 1 + 2 (F1 + 2) as a marker of thrombin generation (7) . On the other hand, enhanced fibrinolytic potential, represented by a decrease in fibrinogen concentration and lower PAI-1 activity, was observed after oral HT (8) . In addition, different HT doses affect coagulation and fibrinolysis in different ways. Recently, our study confirmed increased PAI-1 activity in both ultra-low dose and standard HT after 24 weeks of therapy (9) .
The aim of the present study was to investigate the effects of different doses of oral HT on thrombin generation and fibrinolytic activity after 12 months of treatment.
Material and methods

Participants
This prospective study was performed between January 2013 and July 2015 at the Department of Gynecological Endocrinology in Kracow, Poland. All participants provided informed consent in accordance with the Declaration of Helsinki. The study population (n = 180), aged 45-65 years, was composed of postmenopausal women referred to the Department. All participants suffered from climacteric symptoms such as hot flashes, mood changes and night sweating. Menopause was defined as amenorrhea for more than 12 months with an intact uterus. Postmenopausal status was confirmed in women by follicle-stimulating hormone level (FSH) >30 U/L. Exclusion criteria were: previous thrombotic events (self-reported history of VTE or pulmonary embolism, n = 1), previous history of malignancy (n = 1), medical history of endocrine disorders (self-reported diabetes mellitus, n = 1; hypo-or hyperthyroidism, n = 3) or smoking (n = 4). The study was in two parts. First, we enrolled 60 women who refused to take HT due to their concerns about side effects of the treatment, and they constituted the control group who did not receive any treatment. A further 120 postmenopausal women were divided into two groups depending on the treatment prescribed, in an open-label manner, based on the intensity of climacteric symptoms as evaluated by the physician after a medical interview. The first group (n = 60) consisted of women with severe symptoms who received a standard dose of oral HT (1 mg of 17b-estradiol combined with 5 mg of dydrogesterone; Femoston conti, Abbott, Weesp, Netherlands). The second group (n = 60) consisted of participants with mild climacteric symptoms who obtained ultra-low dose HT (0.5 mg of 17b-estradiol combined with 2.5 mg of dydrogesterone; Femoston mini, Abbott, Olst, Netherlands). None of the study participants had used HT before the study.
A gynecologic examination with a Papanicolaou smear, transvaginal ultrasonography, breast palpation, and mammography were performed at input. At entry and after 12 months of therapy, a general physical examination was performed and bodyweight, body height and blood pressure were measured. Body mass index was calculated by dividing weight in kilograms by square of height in meters.
Laboratory investigations
Venous blood samples were obtained between 8:00-10:00 hours after overnight fasting and a 10-min rest at study entry, and after 12 months (AE8 weeks) of therapy. The levels of fibrinogen, TSH, FSH, estradiol and highsensitivity C-reactive protein (hs-CRP) measurements were determined immediately at our laboratory. Serum FSH and estradiol levels were determined by radioimmunoassay. High sensitivity CRP was measured by nephelometry (Siemens, Marburg, Germany) and fibrinogen levels were marked with the von Clauss method (10) . For coagulation measurements, venous blood was mixed with 3.2% sodium citrate (9:1), centrifuged for 20 min within one hour of blood collection, and stored in aliquots at À80°C for batch analyses. All measurements were performed in duplicate by technicians blinded to the origin of the samples. The inter-and intraassay coefficients of variation for the variables presented below were lower than 7%.
Fibrinolysis proteins. Plasminogen activator inhibitor-1 (PAI-1) activity was determined using a chromogenic assay (Abcam) (11) . Plasma PAI-1 antigen levels were assessed using commercial immunoassays (Berichrom PAI, Behring) (11) . Plasma a 2 -antiplasmin was measured by chromogenic assays (STA Stachrom antiplasmin, Diagnostica Stago, Asni eres, France) (12).
Prothrombin 1 + 2 fragment. F1 + 2 antigen levels were assessed using the ELISA kit with monoclonal antibodies (Enzygnost F1 + 2 Micro; Siemens) (12) .
Antithrombin. AT activity was detected on an automatic analyzer BCS XP using the chromogenic assay (INNOVANCETM AT, Siemens Healthcare Diagnostic, Marburg, Germany) (13) . The reference range for AT activity according to the manufacturer's recommendation was 83-118%.
Statistical analyses
Data are expressed as mean AE SD or median (interquartile range) unless otherwise stated. Statistical analysis was performed using STATISTICA 12.0 software (StatStoft â , Kracow, Poland). The Kolmogorov-Smirnov test was used to assess normality of the distribution. The classical Student's t-test was used to analyze the normal distribution, and the Mann-Whitney U-rank-sum test to analyze abnormal distribution. The net difference between each pair of measurements (at baseline and after 12 months of treatment) was calculated, followed by computation of the difference among treatment groups. Analysis of variance with repeated measures was done to indicate differences between the experimental groups (standard and ultra-low dose HT group) and the control group followed by post hoc Tukey test for intergroup comparison. Women with only baseline samples were excluded from the analyses. Based on our previous study (8) we estimated that 35 women per group were needed to detect a difference between groups using a p-value of 0.05 and an 80% statistical power.
Ethical approval
The Jagiellonian University Medical College Ethical Committee approved the study on 29.11.2012 (Approval no. KBET/347/B/2012).
Results
The final analysis included 175 white, Caucasian women (58 using standard HT, 59 using ultra-low dose HT and 58 controls). The main discontinuation criteria were planned surgery with heparin treatment (n = 3) and abnormal vaginal bleeding (n = 2). None of the women had documented VTE or severe complications during the study period. During the study, all participants taking HT declared a regular intake of the prescribed medication. Compliance with both ultra-low dose HT (97%) and standard HT (95%) was assessed by measurement of pill count. At baseline, no significant differences were found between the groups in either demographic characteristics or any of the variables investigated.
Basic laboratory parameters
The 12-month standard HT was associated with higher fibrinogen concentration (by 30.4%, p = 0.04) ( Table 1) . No similar changes were found in the ultra-low dose HT group. As expected, in both standard and ultra-low dose groups, 12-month HT resulted in increased estradiol levels (by 48.1, p = 0.02 and by 13.1%, p = 0.04, respectively) and decreased FSH concentrations (by 18.3%, p = 0.04 and by 11.0%, p = 0.03, respectively). One-way ANOVA showed between-group differences in both estradiol and FSH mean changes (p = 0.03 for Destradiol and p = 0.04 foc for DFSH) and post-hoc analysis revealed higher estradiol and FSH mean changes from baseline between both treatment groups and the control (Table 1) . Compared with baseline, there were no post-treatment changes in hs-CRP concentrations (Table 1) .
Coagulation
All three groups were well-matched for levels of hemostatic markers. In the standard HT group we observed enhanced coagulation, reflected by increased F1 + 2 levels (by 5.8%, p = 0.04) and decreased AT activity (by 6.1%, p = 0.04).
The 12-month ultra-low dose HT did not alter F1 + 2 or AT values (Table 2) .
ANOVA with post hoc analysis revealed mean increase in F1 + 2 (p = 0.02 for DF1 + 2) in both treatment groups compared with the control group and showed reduction in mean AT activity (p = 0.04 for DAT) in the standard HT group when compared with both the ultralow dose and control group (Table 2) .
Fibrinolysis
The 12-month standard HT led to lower PAI-1 activity and PAI-1 antigen (by À32.4%, p = 0.04 and 9.9, p = 0.03, respectively). Plasma a 2 -antiplasmin levels remained unaltered in this group.
In the ultra-low dose HT group, a decrease in PAI-1 activity (by 19.6%, p = 0.04) and PAI-1 antigen (by 7.8%, p = 0.02) was observed after 12 months of treatment. Intergroup analysis revealed a decrease in both mean PAI-1 activity (p = 0.04 for DPAI-1 activity) and PAI-1 antigen level (p = 0.03 for DPAI-1 antigen) in both standard and ultra-low dose HT groups when compared with the control group ( Table 2) .
Discussion
Hemostatic disorders, both hypercoagulability state and impaired fibrinolysis, may lead to VTE. We marked parameters of this condition among women taking combined oral estrogen and dydrogesterone therapy. Moreover, our study is the first to show significant differences between the ultra-low dose HT and the standard HT in the effects on fibrinolysis and thrombin generation in postmenopausal women after 12 months of treatment.
Activation of coagulation was marked by F1 + 2 assay. Prothrombin 1 + 2 fragment is a peptide which is formed during the conversion of prothrombin to thrombin (14) . Increased levels of F1 + 2 are observed in VTE. Our study demonstrated elevated levels of F1 + 2 only in the standard HT group, indicating that 12 months of therapy increases in vivo thrombin generation. In our other study we also confirmed increased F1 + 2 levels (by 5%, p = 0.004) after 24 weeks of standard HT (9). Elevated F1 + 2 concentrations were reported by Norris et al. (15) in both HT groups (2 mg estradiol + 0.5 mg trimegestrone and 2 mg estradiol + 10 mg dydrogesterone) after 6 months of treatment. This was also demonstrated by Teede et al. (16) after 6 weeks of oral HT containing estradiol and norethisterone acetate. Koh et al. (17) showed increased F1 + 2 levels after 2 months of standard HT. However, similar changes have not been reported in women with transdermal estrogen therapy. Hoibraaten et al. (18) observed reduction in F1 + 2 concentration after 3 and 12 months of therapy with transdermal estradiol with sequential medroxy-progesterine acetate when compared with a control group. Moreover, Scarabin et al. (19) confirmed decreased F1 + 2 levels after 6 months of transdermal estradiol (2.5 mg/day) combined with micronized progesterone (200 mg/day from days [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
Antithrombin is an endogenous anticoagulant that helps control blood clotting. Our study demonstrates dose-dependent decrease in AT, which is a risk factor in thrombosis. We observed AT reduction in patients receiving standard HT after 12 months of therapy. It is interesting that this effect on AT in the ultra-low dose HT was not observed in the present study. Our previous study failed to show changes in AT activity in both treatment groups (9) . To date, only a few studies have reported the effect of estrogen plus dydrogesterone (E+D) on AT. Chang et al. (20) observed AT reduction in both treatment groups with E+D and estrogen plus medroxyprogesterone (MP) after 12 months of therapy. Bonduki et al. (21, 22) conducted two studies where they observed the decrease in AT after oral estrogen plus MP therapy. In another study of continuous estradiol and norethisterone acetate, reduction of AT activity was also observed after 3 months of therapy (23) . To the best of our knowledge, no data evaluating the impact of ultra-low dose HT on AT have been published. Nevertheless, similar changes in AT activity have been confirmed in women after transdermal HT. Bonduki et al. (21, 22) did not observe reduction in AT activity in postmenopausal women after 3, 6 or 12 months of transdermal estrogen plus MP therapy, whereas Hoibraaten et al. (18) reported decrease in AT activity at 3 and 12 months ranging from 3% to 10%. Thus, transdermal HT seems to have a little or no effect on hemostasis.
Elevated activity of PAI-1, a major inhibitor of fibrinolysis, results in deficient plasminogen activation and it is associated with a tendency to thrombosis. Interestingly, our study demonstrated a dose-dependent decrease in PAI-1 activity after 12 months of oral treatment in both the standard and ultra-low dose groups. Similar results were observed by Salobir et al. (23) , who reported a decrease in PAI-1 activity after 3 and 6 months of HT with estradiol and norethisterone acetate. Teede et al. (16) found reduced PAI-1 activity after 6 weeks of the estradiol and norethisterone acetate treatment. In the present study, we also demonstrated a decrease in PAI-1 antigen levels in both treatment groups, which is consistent with our previous study and other prospective studies using combined estrogen plus progestogen HT, indicating that HT increases plasma fibrinolytic inhibitory activity (9, 17, 24) . Taking into account the transdermal form of HT, no apparent changes in PAI-1 activity and PAI-1 antigen concentration were observed. Post et al. reported a 7% decrease in PAI-1 antigen in women on unopposed estradiol (25) . One study confirmed a 6% increase in PAI-1 activity after 3 months of unopposed transdermal transdermal estradiol and a 3% decrease after 12 months of combined transdermal HT when compared with the control group (18) .
Fibrinogen is a glycoprotein synthesized in the liver that participates in blood clot formation. Elevated fibrinogen level is considered to be a independent risk factor for VTE (3, 6) . Our data show that standard HT decreases fibrinogen level after 12 months of therapy. However, there were no significant changes in fibrinogen levels in the ultra-low dose HT group. Other studies reported a similar association of fibrinogen decrease with oral estrogen plus dydrogesterone (E+D) therapy (26, 27) . However, in two studies, Poła c et al. (28, 29) observed a rise in fibrinogen with oral estrogen and dydrogesterone therapy.
Moreover, Bonduki et al. (21) observed an increased fibrinogen level after 12 months in patients receiving both oral CEE and transdermal 17b-estradiol HT. Only two studies found decrease in fibrinogen levels with unopposed transdermal estradiol therapy when compared with baseline (23, 25) . Moreover, in three studies a decrease of up to 9% in fibrinogen levels was observed in comparison with baseline (26, 30) and placebo group (26, 30, 31) .
A relatively small population specimen was taken and our study may thus be statistically underpowered to some negative results. Secondly, our study has different doses of progestins, which may imply an effect of estrogen on hemostasis. Last, we performed a single-center study, in contrast to large multicenter studies, which may have led to a lower statistical power.
Conclusion
Contrary to the standard estrogen plus dydrogesterone treatment, 12 months of ultra-low dose HT revealed positive effects on hemostasis by intensifying fibrinolysis through a decrease in both PAI-1 activity and antigen levels, and with no impact on thrombin generation. This therapy should be considered the safest for women with an increased risk of VTE.
